
Form 4

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden
hours per response0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

/ / Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person*

Golde	Dr. David	W.
(Last)	(First)	(Middle)

- c/o Enzon Pharmaceuticals, Inc. 685 Route 202/206 (Street)
- Bridgewater New Jersey 08807 (City) (State) (Zip)
- 2. Issuer Name and Ticker or Trading Symbol
- ENZON PHARMACEUTICALS, INC. (ENZN)
- 3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)

4. Statement for Month/Year

March 31, 2003

5. If Amendment, Date of Original (Month/Day/Year)

6. Relationship of Reporting Person(s) to Issuer (Check all applicable)

/X/ Director		/	/	10% Ov	vner	
/ / Officer (give	title below)	/	/	Other	(specify	below)

7. Individual or Joint/Group Reporting (Check Applicable Line)

/X/ Form filed by One Reporting Person / / Form filed by More than One Reporting Person

Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	2. Trans- action	2A. Deemed Execution Date,	Execution 3. Trans-		 Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 		
1. Title of Security (Instr. 3)	Date (Month/ Day/ Year)	if any (Month/ Day/ Year)	Code (Instr. 8) 	Amount	(A) or (D)	Price	Trans- action(s) (Instr. 3 and 4)

Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	6. Ownership	
	Form:	
	Direct	7. Nature of
	(D) or	Indirect
	Indirect	Beneficial
1. Title of Security	(I)	Ownership
(Instr. 3)	(Instr. 4)	(Instr. 4)

Table II--Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	 Conversion or 3. Trans- Exercise action Price of Date Deriv- (Month/ 	tion Date, te if any	 Transac- tion Code (Instr. 8) 	 Number of Deriv- ative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)
 Title of Derivative Security (Instr. 3) 		ar) Year)	Code V	(A) (D)
Common Stock Right(1)	1 - for - 1 3/3	1/03	A	441

	-		 Title and Amount of Under Securities (Instr. 3 and 	8. Price of	9. Number of Derivative Securities Benefi- cially Owned Delivation	
 Title of Derivative Security (Instr. 3) 	Date Exercis- able	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)	Following Reported Transaction(s) (Instr. 4)
Common Stock Right(1)	See Footnote (1)	See Footnote (1)	Common Stock	441		441

1. Title of Derivative	10.	Ownership Form of Derivative Securities: Direct (D) or Indirect (I)	11.	Nature of Indirect Beneficial Ownership
I. IICIE OI DELIVACIVE		(1)		Ownersurb
Security (Instr. 3)		(Instr. 4)		(Instr. 4)

D

Common Stock Right(1)

Explanation of Responses:

(1) Securities granted by Enzon Pharmaceuticals, Inc. pursuant to Enzon's 2001 Incentive Stock Plan as compensation for service as an Independent Director during the quarter ended March 31, 2003 and qualified under Rule 16b-3(d). The value of the compensation was \$5,000. In the spring of 2004, each Common Stock right will be exchanged for one share of Common Stock; provided, however, Mr. Golde will be entitled to elect to receive cash for up to 50% of these rights, with the price per right being \$11.35, the fair market value of Enzon's common stock on March 31, 2003.

/s/ Kenneth J. Zuerblis 4/02/03 **Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see instruction 4 (b) (v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.